A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling

A 3-styrylchromone converted from trimebutine 3D pharmacophore possesses dual suppressive effects on RAGE and TLR4 signaling pathways

(2021) Miwa Okazawa et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages

(2021) Natsumi Ogawa et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Quantitative differences between cyclin-dependent kinases underlie the unique functions of CDK1 in human cells

(2021) Ho Wai Lau et al.   Cell Reports

Further Quantitative Structure–Cytotoxicity Relationship Analysis of 3-Styrylchromones

(2020) KOICHI TAKAO et al.   ANTICANCER RESEARCH

Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer

(2020) Jianfeng Liang et al.   BMC Medical Genomics

Myeloid-derived suppressor cells—new and exciting players in lung cancer

(2020) Zhenzhen Yang et al.   Journal of Hematology & Oncology

The HMGB1-RAGE axis modulates the growth of autophagy-deficient hepatic tumors

(2020) Bilon Khambu et al.   Cell Death & Disease

Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors

(2020) Sei-ichi Tanuma et al.   MOLECULES

Trimebutine attenuates high mobility group box 1–receptor for advanced glycation end-products inflammatory signaling pathways

(2020) Shingo Nakajima et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses

(2019) Kenya Tamada et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Inflammation and Cancer: Triggers, Mechanisms, and Consequences

(2019) Florian R. Greten et al.   IMMUNITY

Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy

(2019) Magdalena Jarosz-Biej et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Anticancer effects of a non-narcotic opium alkaloid medicine, papaverine, in human glioblastoma cells

(2019) Mana Inada et al.   PLoS One

Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1

(2019) Carolina M. Gorgulho et al.   Frontiers in Immunology

Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: Implications in DNA repair and immune responses

(2019) Pooja Mandke et al.   DNA REPAIR

Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth

(2019) MANA INADA et al.   ANTICANCER RESEARCH

Structural insights into the active site of poly(ADP-ribose) glycohydrolase using docking modes of 6-hydroxy-3H-xanthen-3-one derivative inhibitors

(2019) Yuto Shibui et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Myeloid-derived suppressor cell: Roles in the tumor microenvironment and tumor radiotherapy

(2018) Zhongnan Yin et al.   INTERNATIONAL JOURNAL OF CANCER

HMGB1 promotes ductular reaction and tumorigenesis in autophagy-deficient livers

(2018) Bilon Khambu et al.   JOURNAL OF CLINICAL INVESTIGATION

RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer—a Review

(2018) Gowri Palanissami et al.   Hormones & Cancer

BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL

(2018) Georgia Greaves et al.   CELL DEATH AND DIFFERENTIATION

The Akt pathway in oncology therapy and beyond (Review)

(2018) George Nitulescu et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Effect of exosomal miRNA on cancer biology and clinical applications

(2018) Zhenqiang Sun et al.   Molecular Cancer

MDSC; the Most Important Cell You Have Never Heard Of

(2018) R.J. Tesi   TRENDS IN PHARMACOLOGICAL SCIENCES

Suppression of HMGB1 Released in the Glioblastoma Tumor Microenvironment Reduces Tumoral Edema

(2018) Bangxing Hong et al.   Molecular Therapy-Oncolytics

Bax, Bak and beyond - mitochondrial performance in apoptosis

(2017) Aida Peña-Blanco et al.   FEBS Journal

High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair

(2017) Marco E. Bianchi et al.   IMMUNOLOGICAL REVIEWS

Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective

(2017) Salvatore Bongarzone et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer

(2017) Peng Zhang et al.   MOLECULAR CANCER RESEARCH

HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma

(2017) Laura Pellegrini et al.   Oncotarget

Myeloid-Derived Suppressor Cells

(2017) Dmitry I. Gabrilovich   Cancer Immunology Research

FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3–CCL2 Signaling

(2016) Xuguang Yang et al.   CANCER RESEARCH

Inhibition of ERK1/2 Signaling Pathway is Involved in Melatonin's Antiproliferative Effect on Human MG-63 Osteosarcoma Cells

(2016) Lifeng Liu et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction

(2016) Michaele B. Manigrasso et al.   Scientific Reports

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

(2015) M Rinaudo-Gaujous et al.   ANNALS OF THE RHEUMATIC DISEASES

Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression

(2015) H Yang et al.   Cell Death & Disease

Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism

(2015) Lianne E. Rotin et al.   Oncotarget

Synthesis and Biological Evaluation of 3-Styrylchromone Derivatives as Free Radical Scavengers and α-Glucosidase Inhibitors

(2014) Koichi Takao et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases

(2014) Hugo González et al.   JOURNAL OF NEUROIMMUNOLOGY

Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein

(2014) Le-Xing Yu et al.   Nature Communications

Cancer Cell Secretion of the DAMP Protein HMGB1 Supports Progression in Malignant Mesothelioma

(2012) S. Jube et al.   CANCER RESEARCH

Targeting the Tumor Microenvironment for Cancer Therapy

(2012) N. E. Sounni et al.   CLINICAL CHEMISTRY

Interleukin-6: from an inflammatory marker to a target for inflammatory diseases

(2012) Mercedes Rincon   TRENDS IN IMMUNOLOGY

Microenvironmental Regulation of Cancer Stem Cell Phenotypes

(2012) Daniela F. Quail et al.   Current Stem Cell Research & Therapy

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

RAGE: a single receptor fits multiple ligands

(2011) Günter Fritz   TRENDS IN BIOCHEMICAL SCIENCES

HMGB1 and RAGE in Inflammation and Cancer

(2010) Gary P. Sims et al.   Annual Review of Immunology

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

Fueling inflammation at tumor microenvironment: the role of multiligand/rage axis

(2009) A. Rojas et al.   CARCINOGENESIS

Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer

(2009) Hye Chung et al.   Journal of Translational Medicine

RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis

(2008) Olga Turovskaya et al.   CARCINOGENESIS

Pathways connecting inflammation and cancer

(2008) Paola Allavena et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Cytokines as a key component of cancer-related inflammation

(2008) Giovanni Germano et al.   CYTOKINE

RAGE signaling sustains inflammation and promotes tumor development

(2008) Christoffer Gebhardt et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE

High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage

(2008) S. S. Lange et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA